Patents by Inventor Nicola Curtin

Nicola Curtin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9791456
    Abstract: The present relates to methods for detecting DNA damage in subjects treated with an ATR inhibitor. More specifically, this invention relates to a method for measuring changes in levels of ?H2AX and/or pChk1Ser345 in, e.g., surrogate tissue cells, following ex vivo stimulation with a DNA damaging agent.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: October 17, 2017
    Assignees: Vertex Pharmaceuticals Incorporated, University of Newcastle Upon Tyne
    Inventors: Susanna Falcon, Philip Reaper, John Pollard, Nicola Curtin, Fiona Middleton, Tao Chen
  • Publication number: 20150247866
    Abstract: The present relates to methods for detecting DNA damage in subjects treated with an ATR inhibitor. More specifically, this invention relates to a method for measuring changes in levels of ?H2AX and/or pChk1Ser345 in, e.g., surrogate tissue cells, following ex vivo stimulation with a DNA damaging agent.
    Type: Application
    Filed: February 27, 2015
    Publication date: September 3, 2015
    Inventors: Susanna Falcon, Philip Reaper, John Pollard, Nicola Curtin, Fiona Middleton, Tao Chen
  • Patent number: 8999632
    Abstract: The present relates to methods for detecting DNA damage in subjects treated with an ATR inhibitor. More specifically, this invention relates to a method for measuring changes in levels of ?H2AX and/or pChk1Ser345 in, e.g., surrogate tissue cells, following ex vivo stimulation with a DNA damaging agent.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: April 7, 2015
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Susanna Falcon, Philip Reaper, John Pollard, Nicola Curtin, Fiona Middleton, Tao Chen
  • Publication number: 20140134596
    Abstract: The present relates to methods for detecting DNA damage in subjects treated with an ATR inhibitor. More specifically, this invention relates to a method for measuring changes in levels of ?H2AX and/or pChk1Ser345 in, e.g., surrogate tissue cells, following ex vivo stimulation with a DNA damaging agent.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 15, 2014
    Inventors: Susanna Falcon, Philip Reaper, John Pollard, Nicola Curtin, Fiona Middleton, Tao Chen
  • Patent number: 7531530
    Abstract: The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: May 12, 2009
    Assignees: Cancer Research Technology Limited, Pfizer
    Inventors: Thomas Helleday, Nicola Curtin
  • Patent number: 7351701
    Abstract: The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: April 1, 2008
    Assignees: Cancer Research Technology Limited, Pfizer, Inc.
    Inventors: Thomas Helleday, Nicola Curtin
  • Publication number: 20070238729
    Abstract: The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R1 and R2 are independently hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR4 and O, O and CR?4 and NR?4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R3 and R4 or R?4 is an optionally substituted C3-20 heteroaryl or C5-20 aryl group, and the other of R3 and R4 or R?4 is H, or R3 and R4 or R?4 together are -A-B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.
    Type: Application
    Filed: June 5, 2007
    Publication date: October 11, 2007
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Niall Martin, Graeme Smith, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, Hilary Calvert, Nicola Curtin, Laurent Rigoreau, Xiao-ling Cockcroft, Vincent Junior Loh, Paul Workman, Florence Raynaud, Bernard Nutley
  • Publication number: 20070238731
    Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(?O)— or —O—; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3 or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(?O)—NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, o
    Type: Application
    Filed: September 20, 2005
    Publication date: October 11, 2007
    Applicants: KUDOS PHARMACEUTICALS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Graeme Smith, Niall Martin, Roger Griffin, Bernard Golding, Ian Hardcastle, Kappusamy Saravanan, David Newell, Hilary Calvert, Nicola Curtin, Keith Menear, Marc Hummersone
  • Publication number: 20070072841
    Abstract: The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
    Type: Application
    Filed: July 23, 2004
    Publication date: March 29, 2007
    Applicants: CANCER RESEARCH TECHNOLOGY LIMITED, PFIZER INC.
    Inventors: Thomas Helleday, Nicola Curtin
  • Publication number: 20070049588
    Abstract: A compound of formula (I): and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, and their use in treating diseases ameliorated by the inhibition of ATM.
    Type: Application
    Filed: August 30, 2006
    Publication date: March 1, 2007
    Applicant: KuDOS Pharmaceuticals Limited
    Inventors: Graeme Smith, Niall Martin, Andrew Slade, Keith Menear, Marc Hummersone, Xiao-Ling Cockcroft, Ian Matthews, Laurent Rigoreau, Roger Griffin, David Newell, Nicola Curtin
  • Publication number: 20060264427
    Abstract: Compounds of formula I: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N;and (iii) CH, O, C; the dotted lines represent two double bonds in the appropriate locations; and where Z is selected from S, O, C(?O), CH2 and NH are disclosed for use in inhibiting DNA-PK.
    Type: Application
    Filed: April 13, 2006
    Publication date: November 23, 2006
    Applicants: KuDOS Pharmaceuticals Limited, Cancer Research Technology Limited
    Inventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Xiao-ling Cockcroft, Mark Frigerio, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, HiIary Calvert, Nicola Curtin, Kappusamy Saravanan, Marine Desage-El Murr
  • Publication number: 20060264623
    Abstract: Compounds of formula l: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N;and (iii) CH, O, C; are disclosed for use in inhibiting DNA-PK.
    Type: Application
    Filed: April 13, 2006
    Publication date: November 23, 2006
    Applicants: KuDOS Pharmaceuticals Limited, Cancer Research Technology Limited
    Inventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Xiao-ling Cockcroft, Mark Frigerio, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, Hilary Calvert, Nicola Curtin, Marine Desage-El Murr
  • Publication number: 20060106025
    Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(?O)— or —O—; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3, or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(?O)—NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl g
    Type: Application
    Filed: September 20, 2005
    Publication date: May 18, 2006
    Applicants: Kudos Pharmaceuticals Limited, Cancer Research Technology Limited
    Inventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Laurent Rigoreau, Roger Griffin, Bernard Golding, David Newell, Hilary Calvert, Nicola Curtin, Ian Hardcastle, Kappusamy Saravanan
  • Publication number: 20050143370
    Abstract: The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
    Type: Application
    Filed: July 23, 2004
    Publication date: June 30, 2005
    Inventors: Thomas Helleday, Nicola Curtin
  • Publication number: 20050107367
    Abstract: The present invention provides compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein R1 and R2 are independently hydrogen, an option ally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and R3 is an optionally substituted C3-20 heterocyclyl or C5-20 aryl group, and their use as pharmaceuticals, particularly in treating diseases which are retroviral mediated or ameliorated by the inhibition of DNA-PK,
    Type: Application
    Filed: August 14, 2002
    Publication date: May 19, 2005
    Inventors: Niall Martin, Graeme Cameron Smith, Roger Griffin, Bernard Golding, Ian Hardcastle, Laurent Rigoreau, David Newell, Hilary Calvert, Nicola Curtin, Paul Workman, Florence Raynaud, Bernard Nutley
  • Patent number: 6156739
    Abstract: Phosphate derivatives are disclosed of quinazolinone compounds having structural formula (I) or a pharmaceutically acceptable salt thereof, wherein X' represent hydroxyl, alkyl, alkoxy, or O--Z where Z is a phosphate or phosphate derivative; Y' represents hydrogen, alkyl or an optionally substituted aryl group or optionally substituted aralkyl group; and R' is hydrogen, alkyl, or CH.sub.2 --O--Z where Z is again a phosphate or phosphate derivative; subject to the proviso that if neither X' nor R' contains Z, Y' is an aryl or aralkyl group having an O--Z substituent therein with Z once again being a phosphate or phosphate derivative as hereinabove defined. These compounds are useful as prodrugs for providing active PARP inhibiting substances for medical use in conjunction with a cytotoxic drug or radiotherapy in order to increase the effectiveness of the latter, especially in connection with antitumor treatment.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: December 5, 2000
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger John Griffin, Alan Hilary Calvert, Jane Nicola Curtin, David Richard Newell, Bernard Thomas Golding